Jul 05, 2012 - Oncology Supportive Care

Terapio is commercializing TPO-7640 for oncology supportive care. Most cancer treatments utilize cytotoxic radiotherapy or chemotherapeutic agents, or a combination thereof, which target rapidly diving cells including the mucosal membranes. This causes painful inflammation and ulceration and can lead to development of oral mucositis, esophagitis, proctitis or vaginitis. A similar mechanism of action of RLIP76 as shown in Terapio’s radiation countermeasure and chemical countermeasure studies directly applies to these conditions because these side effects of cancer therapy are initiated by the generation of oxidative stress. TPO-7640 is being developed as a therapeutic to be given before (prophylactic) or after (mitigator) radiation or chemotherapy to prevent or treat these often debilitating conditions.

-->

Terapio

/Tĕ•rah•pē•ō/

means therapy in Esperanto, an international, constructed language introduced by Dr. L.L. Zamenhof in 1887.